Harpoon Therapeutics Bolsters Leadership with Key Executive Appointments
In a strategic move to fortify its leadership, Harpoon Therapeutics, a clinical-stage immunotherapy company, has announced the addition of James Bucher, J.D., as the new Chief Legal Officer, and the elevation of Wendy Chang to Chief People Officer. These appointments come at a critical time as the company seeks to advance its mission of developing innovative T cell engagers to harness the body’s immune system in the fight against diseases.
James Bucher joins the company with an extensive background in legal affairs, particularly within the life sciences sector. His career spans over thirty years, with notable positions at Eliem Therapeutics, Alder Biopharmaceuticals, and Exelixis. Bucher’s role at Harpoon will involve the oversight of corporate governance, intellectual property, and compliance matters. His academic background is equally impressive, holding a J.D. with distinction from Emory University School of Law and a B.A. from Colgate University.
The promotion of Wendy Chang to Chief People Officer is a testament to her impactful contributions to the company since her arrival in 2022. Chang’s two decades of human resources experience in the life sciences industry have equipped her with the skills to align talent strategies with the company’s objectives. Her career includes senior roles at IDbyDNA and Gilead Sciences. Chang’s educational qualifications include a B.S. in accounting and business management from the University of California, Riverside, and she is a Global Fellow of Talent Management from The Wharton School of the University of Pennsylvania.
The company’s dedication to developing T cell engagers is reflected in its efforts to strengthen the executive team. This expansion is part of Harpoon’s commitment to advancing clinical development and achieving significant milestones in the forthcoming year. The collective experience of the leadership team is anticipated to be pivotal in guiding the company through its next growth and development phases.
The recent executive enhancements at Harpoon Therapeutics mark a significant step in reinforcing the company’s dedication to its mission and organizational culture. The integration of James Bucher as Chief Legal Officer and the advancement of Wendy Chang to Chief People Officer are expected to be instrumental in navigating the intricacies of the clinical-stage immunotherapy domain. Their combined expertise will be essential in leading the company’s innovative endeavors to exploit the immune system’s capabilities in disease treatment. As Harpoon Therapeutics progresses, its fortified executive team will be crucial in the pursuit of its patient-centric objectives.
